M D..,., M. M P.. P H., H, F. F A.. A C..S..

Size: px
Start display at page:

Download "M D..,., M. M P.. P H., H, F. F A.. A C..S.."

Transcription

1 Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical Director Aultman Cancer Center Radical Mast. Operable Breast Cancer N=179 Clinically Node-Negative Negative Total Mast. HR: 1.3 (9% CI ; P=.72) NSABP B-4 Total Mast. + XRT Overall Survival Global p=.68 Patients Deaths RM TMR TM % of pts in the RM group had + nodes Thus, only about 29 pts contribute to the comparison of RM with TM (about 14/group) Years Fisher B: NEJM, 22 NSABP B-32 Schema NSABP B-32 Clinically Negative Axillary Nodes N=611 GROUP 1 Biopsy Axillary Dissection Stratification Age Clinical Tumor Size Type of Surgery Randomization GROUP 2 Biopsy* *Axillary node dissection only if the SN is positive Technical Results Identification Rate: 97% False Negative Rate: 9.7% Average number of SNs: 2.9 Factors significantly affecting ID rate: Age, Tumor Size and Tumor Location Factors significantly affecting FN rate: Type of Biopsy and Number of Removed SNs Krag D, et al: Lancet Oncol 27 4 B-32 SN Pos Clinically Negative Axillary Nodes GROUP 1 SN +AD SN Neg (SN+AD) Randomization Intraop cytology & postop HE SN pos + AD 829 pts FU 793 pts GROUP 2 SN Stratification Age Clinical Tumor Size Type of Surgery SN Neg (SN only) FU 1,97 pts 2,11 pts Krag D et al: ASCO 21 Abstr. LBA % Surviving NSABP Protocol B-32 Overall Survival for SN Negative Patients Trt N Deaths SNR+AD SNR HR=1.2 p=.117 Data as of December 31, Years After Entry * 3 deaths triggered the definitive analysis * 39 reported as of 12/31/29 Krag D et al: Lancet Oncol 21 Page 1 1

2 % Disease-Free NSABP Protocol B-32 Disease-Free Survival for SN Negative Pts Trt N Events SNR+AD SNR HR=1. p=.42 Data as of December 31, Years After Entry Krag D et al: Lancet Oncol 21 B-32 Hazard Ratios Between Groups According to Site of Treatment Failure Dead, NED 2nd cancers Opposite Breast Cancers Distant Recurrences Local Regional Recurrences All events HR= 1. SNR better Hazard Ratio SNR+AD better Krag D et al: Lancet Oncol 21 NSABP B-32: Local and Regional Recurrences as First Events 9 NSABP B-32: Significantly Lower Morbidity Without vs. With ALND 1 Patients (%) Local Axillary Recurrence Type SNR + ALND (n = 197) SNR (n = 211) Extra-axillary axillary Patients (%) P < Shoulder Abduction Deficit 28 P <.1 17 Arm Volume Difference > % P < Arm Numbness 13 SNR + ALND (n = 197) SNR (n = 211) P <.1 7 Arm Tingling Krag D et al: Lancet Oncol 21 Ashikaga T: J Surg Oncol 21 B-32: Conclusion No significant differences were observed OS, DFS, or Regional Control Morbidity decreased When the SN is negative, SN surgery alone with no further AD is appropriate, safe, and effective therapy for breast cancer patients with clinically negative lymph nodes. Krag D et al: Lancet Oncol 21 B-32 In Perspective Could the B-32 trial ever show more than 2% difference in overall survival? SNB + AND 287 pts 1,97 pts* 7 Pts Had Negative SN and Positive NSNs on AND *3 pts had no F/U ID Rate 97% 17 pts had no SNB 829 pts 793 pts Node-Positive SND + AND 2.6% Reg. Nodal Recurrence 8 vs. 14 SNB Alone 284 pts 2,11 pts About 7 Pts Positive NSNs and did not have AND Page 2 2

3 B-32 In Perspective Could the B-32 trial ever show more than 2% difference in overall survival? SNB + AND 287 pts 1,97 pts* 7 Pts Had Negative SN and Positive NSNs on AND *3 pts had no F/U ID Rate 97% 17 pts had no SNB 829 pts 793 pts Node-Positive SND + AND 2.6% Reg. Nodal Recurrence 8 vs. 14 SNB Alone 284 pts 1:4 Dilution of Any Real Benefit from ALND! 2,11 pts About 7 Pts Positive NSNs and did not have AND NSABP B-32: Occult Metastases Clinically Negative Axillary Nodes GROUP 1 Biopsy Axillary Dissection Randomization GROUP 2 Biopsy* *Axillary node dissection only if the SN is positive IHC and detailed pathologic examination of the SNs performed centrally and results were not disclosed Weaver D et al: N Engl J Med NSABP B-32: Effect of Occult Metastases on Survival in Node-Negative Negative Breast Cancer NSABP B-32: Effect of Occult Metastases on Survival in Node-Negative Negative Breast Cancer 1.9% Weaver D et al: N Engl J Med 211 Weaver D et al: N Engl J Med 211 Individualizing Loco-Regional Therapy with Neoadjuvant Chemotherapy Achievements Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Conversion of patients with inoperable tumors to operable candidates Conversion of mastectomy candidates to candidates for BCS Improvement in cosmesis by reducing the size of lumpectomy in BCS candidates with large tumors Page 3 3

4 Individualizing Loco-Regional Therapy with Neoadjuvant Chemotherapy Promises Reduction in the extent of axillary surgery by down-staging involved axillary nodes (SNB) Reduction in the extent of L-R XRT by down- staging primary tumors and axillary nodes Potential for eliminating some loco-regional therapy altogether (surgery or XRT) with the use of more active regimens and/or with appropriate patient selection with biomarkers Surgical Management of Axillary Nodes After NC NC down-stages axillary nodes in 2-4% of the patients Potential for decreasing the extent of axillary surgery with SNB AC NSABP B-18 % Conversion From To 19 FEC EORTC AT CMF AC TXT ECTO NSABP B-27 27* *Assuming 3% nodal down- staging with neoadjuvant AC SNB After NC Multi-Center Studies: NSABP B-27 (n=428) Identification Rate: 8% With blue dye: 78% With isotope + blue dye: 88-89% 89% False Negative Rate: 11% With blue dye: 14% With isotope + blue dye: 8.4% Clinically : 12.4% Clinically : 7.% P=.1 Mamounas EP: J Clin Oncol, 2 SNB After NC Meta-Analysis of Single-Institution and Multi-Center Studies 24 studies 1779 patients Identification Conclusion: Rates: 63-1% Pooled SNB is estimate: a reliable 89.6% tool for False planning Negative treatment Rates: -33% after NC Pooled estimate: 8.4% Kelly A et al: Acad Radiol 29 Author Shen, 26 Lee, 26 Newman, 27 SNB After NC: Single Institution Series Positive Axillary Nodes Before NC Stage # Pts (Node +) Success Rate ( %) FN Rate (%) Accurate T1-T4, T4, N1-N3N3 69(4) 93 2 No T1-T4, T4, N1 (Palpable and FNA (+) or > 1cm thick with loss of fat hilum on US and SUV > 2. Resectable T1-3, N1 (FNA (+) under US) 219 (124) 78 6 Yes 4 (28) Yes All 328 (172) Z171: SLNB + AND After NC T1-4 N1-2 invasive breast cancer (pretreatment axillary ultrasound with FNA or core biopsy documenting axillary metastases) REGISTER* Patients receive neoadjuvant chemotherapy (stratify patients by age, stage and number of cycles and type of chemotherapy) Target REGISTER* Accrual: pts SLN and ALND Page 4 4

5 SNB Before NC: Pros and Cons Helpful if the SN is negative Patients with large operable breast cancer have high likelihood of positive nodes (-7%) Does not take advantage of the downstaging effects of NC on nodes: 3-4% conversion from (+) to (-) Requires two surgical procedures SNB Before NC: Selection of Loco-Regional XRT? Breast XRT: Should be always given after lumpectomy Can We Use Tumor and Nodal Chest Wall and Regional XRT: Consider factors predicting local-regional failure after NC Response to NC in Order to Individualize the Use of L-R XRT? These factors may predict LR failure more accurately than the original pathologic nodal status before NC Combined Analysis of B-18/B-27 Independent Predictors of LRF Lumpectomy + XRT (189 Pts, 19 Events) Age (> years vs. < years) Clinical Nodal Status (+) vs. (-) Breast/Nodal Path Status Node(-)/No vs. Node(-)/ Node(+) vs. Node(-) / Mastectomy (17 Pts, 128 Events) Clinical Tumor Size (> cm vs. < cm) Clinical Nodal Status (+) vs. (-) Breast/Nodal Path Status Node(-)/No vs. Node(-)/ Node(+) vs. Node(-) / Mamounas et al: ASCO Breast 21, Abstr n= Year Cum. Incidence of LRF Lumpectomy Patients, > years n= No I B TR n= Clin. Clin. n=31 6. n= No n= Mamounas et al: ASCO Breast 21, Abstr Year Cum. Incidence of LRF Lumpectomy Patients, < years n=13 n= No I B TR n= Clin. Clin. n= n= No n= Mamounas et al: ASCO Breast 21, Abstr n= Year Cum. Incidence of LRF Mastectomy Patients, < cm Che st Wa l l No n=21 Clin. Clin. n=178 n=183 n= No n= Mamounas et al: ASCO Breast 21, Abstr. 9 Page

6 Year Cum. Incidence of LRF Mastectomy Patients, > cm C he st Wa l l No Clin. Clin. n=179 n=16 n=9 n=11 n= n= No Mamounas et al: ASCO Breast 21, Abstr. 9 1-year probability (%) of being Local Failure Free 1-Year Probability of LRF Nomogram for Prediction of 1-Year Rate of LRF After NC Lumpectomy + XRT Age at Entry (Years) Age at Entry (Years) CNS pos, CNS pos,, No CNS pos,, CNS neg, CNS neg,, No CNS neg,, 1-Year 1-year probability Probability (%) of being Local Failure of LRF Free Nomogram for Prediction of 1-Year Rate of LRF After NC Mastectomy CNS pos, CNS pos,, No CNS pos,, CNS neg, CNS neg,, No CNS neg,, Clinical Tumor Size at Entry (cm) Clinical Tumor Size (cm) Summary/Conclusions SNB alone is the standard of care for staging the axilla in patients with negative SNB SNB alone appears reasonable for patients with occult mets, micromets or macromets (not identified intraoperatively or by routine H & E assessment) Following neoadjuvant chemotherapy loco-regional therapy can be tailored based on clinico-pathologic tumor response in the breast and axillary nodes This approach holds great promise as NC regimens (+ targeted biologics) become considerably more effective and as genomic and imaging technology allows for more accurate prediction and identification of pathologic complete responders 34 Page 6 6

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical

More information

NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions

NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions 1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health

More information

Page 1. AD vs. no AD. Survival. Randomized Trials. All trials reported higher survival in the AD group. Years. Node-NegativeNegative

Page 1. AD vs. no AD. Survival. Randomized Trials. All trials reported higher survival in the AD group. Years. Node-NegativeNegative Sentinel Node Biopsy: The Past, The Present, and The Future Thomas B. Julian, M.D., F.A.C.S. Associate Professor of Human Oncology Drexel University College of Medicine Director of Breast Surgical Oncology

More information

Loco-Regional Management After Neoadjuvant Chemotherapy

Loco-Regional Management After Neoadjuvant Chemotherapy 1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,

More information

Loco-Regional Management After Neoadjuvant Chemotherapy

Loco-Regional Management After Neoadjuvant Chemotherapy 1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,

More information

Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer

Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer Wendy A. Woodward, M.D. Ph.D. A sociate Profesor Section Chief, Breast Radiation Oncology

More information

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant

More information

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective :$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical

More information

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer - Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the

More information

Should we still be performing IHC on all sentinel nodes?

Should we still be performing IHC on all sentinel nodes? Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami

More information

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic

More information

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Rebecca Warburton MD Department of Surgery, University of British Columbia Mount Saint Joseph Hospital, Providence Health Care

More information

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical

More information

Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin

Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin 1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective

More information

Neoadjuvant Treatment of. of Radiotherapy

Neoadjuvant Treatment of. of Radiotherapy Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect

More information

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? 1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program

More information

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications

More information

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016 Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient

More information

Results of the ACOSOG Z0011 Trial

Results of the ACOSOG Z0011 Trial DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival

More information

Surgical Issues in Neoadjuvant Chemotherapy

Surgical Issues in Neoadjuvant Chemotherapy 14 th Bossche Mamma Congress Ruwenbergstraat 7 5271 AG Sint Michielsgestel June 14, 2016 Surgical Issues in Neoadjuvant Chemotherapy Tari A. King MD FACS Chief, Breast Surgery Dana Farber/Brigham and Women

More information

Evaluating the Z011 study and how local-regional therapy for early breast cancer may change

Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Karen Hoffman, M.D., M.H.Sc., M.P.H. Dept of Radiation Oncology The University of Texas MD Anderson Cancer Center

More information

Surgical Management of the Axilla

Surgical Management of the Axilla Surgical Management of the Axilla Jean-Francois Boileau, MD, MSc, FRCSC Surgical Oncologist, Montreal Jewish General Hospital Segal Cancer Centre Associate Member, Department of Oncology, McGill University

More information

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast

More information

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,

More information

Ultrasound or FNA for Predicting Node Positive in Breast Cancer

Ultrasound or FNA for Predicting Node Positive in Breast Cancer Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital

More information

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,

More information

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically

More information

Evolution of Regional Nodal Management of Breast Cancer

Evolution of Regional Nodal Management of Breast Cancer Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State

More information

Sentinel Lymph Node Biopsy for Breast Cancer

Sentinel Lymph Node Biopsy for Breast Cancer Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor

More information

Genomic Profiling of Tumors and Loco-Regional Recurrence

Genomic Profiling of Tumors and Loco-Regional Recurrence 1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,

More information

Evaluation of the Axilla Post Z-0011 Trial New Paradigm

Evaluation of the Axilla Post Z-0011 Trial New Paradigm Evaluation of the Axilla Post Z-0011 Trial New Paradigm Belinda Curpen, MD, FRCPC; Tetyana Dushenkovska; Mia Skarpathiotakis MD, FRCPC; Carrie Betel, MD, FRCPC; Kalesha Hack, MD, FRCPC; Lara Richmond,

More information

Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)

Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both

More information

Principles of breast radiation therapy

Principles of breast radiation therapy ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital

More information

Recent Update in Surgery for the Management of Breast Cancer

Recent Update in Surgery for the Management of Breast Cancer Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National

More information

CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?

CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? I have no Disclosures Wolfgang Gatzemeier Breast Unit Milan, Italy 17th ESO-ESMO- EONS Masterclass in Clinical Oncology 24-29 MARCH 2018 Optimal

More information

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit. AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In

More information

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:

More information

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged: Axillary Node Recurrence N.L. Davis Associate Professor of Surgery, UBC Head of Surgical Oncology, BCCA Relevance In an attempt to minimize long term complications and to maximize cancer control, the management

More information

THE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital

THE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital THE SURGEON S ROLE: THE AXILLA Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital What are the concerns with treatment to the axilla Not necessary for

More information

03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.

03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology

More information

Evolution of Breast Surgery

Evolution of Breast Surgery Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,

More information

Surgical Issues in Melanoma

Surgical Issues in Melanoma Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical

More information

Surgery for Breast Cancer

Surgery for Breast Cancer Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85

More information

Surgical Considera0ons with Neoadjuvant Treatment in Breast Cancer

Surgical Considera0ons with Neoadjuvant Treatment in Breast Cancer Surgical Considera0ons with Neoadjuvant Treatment in Breast Cancer David R McCready MD MSc FRCSC FACS GaAuso Chair in Breast Surgical Oncology Professor of Surgery, University of Toronto Princess Margaret

More information

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation

More information

ALND. Dr. MJ Vrancken

ALND. Dr. MJ Vrancken ALND Dr. MJ Vrancken ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice opera8on; dorsal approach 2 ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice

More information

ARROCase - April 2017

ARROCase - April 2017 ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year

More information

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy

More information

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic

More information

Advances in Localized Breast Cancer

Advances in Localized Breast Cancer Advances in Localized Breast Cancer Melissa Camp, MD, MPH and Fariba Asrari, MD June 18, 2018 Moderated by Elissa Bantug 1 Advances in Surgery for Breast Cancer Melissa Camp, MD June 18, 2018 2 Historical

More information

EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY

EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY AXILLARY LYMPH NODE METASTASIS Axillary lymph node metastasis is one of the most

More information

Lecture 5. Primary systemic therapy: clinical and biological endpoints

Lecture 5. Primary systemic therapy: clinical and biological endpoints Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for

More information

Introduction. Approximately 20% of invasive breast cancers

Introduction. Approximately 20% of invasive breast cancers Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy

More information

Practice of Axilla Surgery

Practice of Axilla Surgery Summer School of Breast Disease 2016 Practice of Axilla Surgery Axillary Lymph Node Dissection & Sentinel Lymph Node Biopsy 연세의대외과 박세호 Contents Anatomy of the axilla Axillary lymph node dissection (ALND)

More information

Treatment of the Axilla for Breast Cancer:

Treatment of the Axilla for Breast Cancer: Treatment of the Axilla for Breast Cancer: V. Suzanne Klimberg, M.D., Ph.D. Courtney M Townsend, Jr. M.D. Distinguished Chair in General Surgery Chief of Surgical Oncology and Medical Director of the University

More information

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015 Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable

More information

Spotlights on the surgery role at San Antonio

Spotlights on the surgery role at San Antonio Spotlights on the surgery role at San Antonio Riccardo Masetti, MD Professor of Surgery Director, Multidisciplinary Breast Center Catholic University Rome, Italy Roma, 21 maggio 2017 Prof. Masetti has

More information

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer

More information

Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy

Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Eun Yoon Cho, MD, PhD Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University

More information

ASCO and San Antonio Updates

ASCO and San Antonio Updates ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs

More information

NeoadjuvantTreatment In BC When, How, Who?

NeoadjuvantTreatment In BC When, How, Who? NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of

More information

Case Conference: Post-Mastectomy Radiotherapy

Case Conference: Post-Mastectomy Radiotherapy Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro

More information

BREAST CANCER SURGERY. Dr. John H. Donohue

BREAST CANCER SURGERY. Dr. John H. Donohue Dr. John H. Donohue HISTORY References to breast surgery in ancient Egypt (ca 3000 BCE) Mastectomy described in numerous medieval texts Petit formulated organized approach in 18 th Century Improvements

More information

Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift. Edi Brogi MD PhD Attending Pathologist Director of Breast Pathology

Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift. Edi Brogi MD PhD Attending Pathologist Director of Breast Pathology Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift Edi Brogi MD PhD Attending Pathologist Director of Breast Pathology Sentinel Lymph Nodes 2014 AJCC 2010 staging Micrometastases Occult metastases

More information

Who is the Ideal Candidate for PEG Intron?

Who is the Ideal Candidate for PEG Intron? Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction

More information

Updates on management of the axilla in breast cancer the surgical point of view

Updates on management of the axilla in breast cancer the surgical point of view Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of

More information

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy

More information

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical

More information

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia

More information

Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective

Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,

More information

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery Ann Surg Oncol (2015) 22:1128 1132 DOI 10.1245/s10434-014-4090-y ORIGINAL ARTICLE BREAST ONCOLOGY Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing

More information

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Quality ID #264: Sentinel Lymph de Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Maria João Cardoso, MD, PhD

Maria João Cardoso, MD, PhD Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No

More information

Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study

Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study [ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong

More information

Evolving Practices in Breast Cancer Management

Evolving Practices in Breast Cancer Management Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand

More information

Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy

Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy ONCOLOGY REPORTS 15: 927-931, 2005 927 Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy YOSUKE TANAKA 1, HIRONORI MAEDA 2, YASUHIRO OGAWA 3, AKIHITO NISHIOKA 3, SATOSHI

More information

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay

More information

Molecular Enhancement of Sentinel Node Evaluation

Molecular Enhancement of Sentinel Node Evaluation Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of

More information

Sentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner

Sentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated

More information

Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage

More information

San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective. Disclosures

San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective. Disclosures San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective January 18, 2011 Association of Northern California Oncologists Steven Chen, MD, MBA Chief, Breast Surgery University of

More information

Can We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D.

Can We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D. Can We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D. I have no relevant financial relationship with commercial interests to disclose. More

More information

Savitri Krishnamurthy, MD 1

Savitri Krishnamurthy, MD 1 EVOLVING TRENDS IN PATHOLOGIC EVALUATION OF AXILLARY LYMPH NODES IN BREAST CANCER Savitri Krishnamurthy, M.D. Professor Department of Pathology University of Texas M. D. Anderson Cancer Center AXILLARY

More information

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI % 38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype

More information

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer

More information

Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy

Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy The London Cancer Alliance West and South Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy Dimitri J Hadjiminas, MD, MPhil, FRCS (Consultant Breast & Endocrine Surgeon Imperial

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION TYPE:

More information

ASTRO econtouring for Lymphoma. Stephanie Terezakis, MD

ASTRO econtouring for Lymphoma. Stephanie Terezakis, MD ASTRO econtouring for Lymphoma Stephanie Terezakis, MD Disclosures No conflicts to disclose 1970 Total Lymphoid Irradiation (TLI) 1995 Involved-Field Radiotherapy (IFRT) 2008 Involved Node Radiotherapy

More information

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to: 1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications

More information

Whole Breast Irradiation: Class vs. Hypofractionation

Whole Breast Irradiation: Class vs. Hypofractionation Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer

More information

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed

More information

BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO

BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor

More information

Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial

Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.

More information

Locally Advanced Breast Cancer: Systemic and Local Therapy

Locally Advanced Breast Cancer: Systemic and Local Therapy Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore

More information

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department

More information

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane

More information

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein

More information

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney

More information

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine

More information

Review Article Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients

Review Article Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients BioMed Research International Volume 2015, Article ID 405949, 5 pages http://dx.doi.org/10.1155/2015/405949 Review Article Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients

More information